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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) was
requested to consider in the Flavouring Group Evaluation 205 (FGE.205), the additional data on
genotoxicity submitted by the Industry on two representative substances, oct-1-en-3-one [FL-no:
07.081] and pent-1-en-3-one [FL-no: 07.102], from subgroup 1.2.2 of FGE.19. The Panel concluded
that both substances were weakly genotoxic in bacteria with pent-1-en-3-one being the most potent
(previously available data). In these assays, the representative substances were highly cytotoxic with a
steep toxicity curve and with a very narrow concentration range resulting in mutagenicity. Both
substances were also tested in mammalian cells for gene mutations at the hprt locus and for structural
and numerical chromosomal aberrations in the micronucleus assay. Also in mammalian cells, the test
substances were highly cytotoxic. The Panel considered that the positive effects in the bacterial
mutagenicity assays of the two representative substances cannot be overruled by the one negative
and one equivocal gene mutation test in mammalian cells. Therefore, the Panel recommended to test
the most potent of the representative substances, pent-1-en-3-one, in an in vivo Comet assay on the
ﬁrst site of contact (e.g. the stomach or duodenum) and on the liver. The Industry has now submitted
new data, a combined micronucleus and Comet assay for pent-1-en-3-one, with scoring in the liver
and duodenum, and an Ames test and a Comet assay with scoring in the liver for oct-1-en-3-one.
Based on these new data, the Panel concluded that the concern for a genotoxic potential could be
ruled out for the two representative substances and accordingly for the remaining 11 substances in
FGE.205Rev1. The 13 substances in FGE.205Rev1 can therefore be evaluated via the Procedure.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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Summary
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes,
Flavourings and Processing Aids (the Panel) to provide scientiﬁc advice to the Commission on the
implications for human health of chemically deﬁned ﬂavouring substances used in or on foodstuffs in
the Member States. In particular, the Panel was asked to evaluate ﬂavouring substances using the
Procedure as referred to in the Commission Regulation (EC) No 1565/2000.
Flavouring Group Evaluation 205 (FGE.205), corresponding to subgroup 1.2.2 of FGE.19, concerns
four a,b-unsaturated aliphatic ketones with a terminal double bond and nine precursors for such
ketones. The 13 substances under consideration in the present evaluation are a,b-unsaturated ketone
structures (or can be metabolised to such) which are considered to be structural alerts for
genotoxicity. The data on genotoxicity previously available did not rule out the concern for
genotoxicity. The Panel has identiﬁed two substances in subgroup, 1.2.2, oct-1-en-3-one [FL-no:
07.081] and pent-1-en-3-one [FL-no: 07.102], which will represent the other 11 substances in this
subgroup. For these two substances, genotoxicity data according to the test strategy worked out by
the Panel have been requested.
The Industry has subsequently submitted data concerning genotoxicity studies for the two
representative substances of subgroup 1.2.2.
According to these data, both oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one [FL-no: 07.102]
were mutagenic in bacteria, and highly cytotoxic with a steep toxicity curve and with a very narrow
concentration range resulting in mutagenicity. Both substances were also tested in mammalian cells for
gene mutations at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus and for structural
and numerical chromosomal aberrations in the micronucleus assay. Also in mammalian cells, the test
substances were highly cytotoxic. In the ﬁrst opinion on FGE.205, the Panel considered that the
positive effects in the bacterial mutagenicity assays of the two representative substances cannot be
overruled by the one negative and one equivocal gene mutation test in mammalian cells. Therefore,
the Panel recommended to test the most potent of the representative substances, pent-1-en-3-one, in
an in vivo Comet assay on the ﬁrst site of contact (e.g. the stomach or duodenum) and on the liver.
In response to the request in FGE.205, the Industry has now submitted new data, a combined
micronucleus and Comet assay for pent-1-en-3-one with scoring in the liver and duodenum, and an
Ames test and a Comet assay with scoring in the liver for oct-1-en-3-one. Based on these new data,
the Panel concluded that the concern for a genotoxic potential could be ruled out for the two
representative substances [FL-no: 07.081 and 07.102] and accordingly for the remaining 11 substances
[FL-no: 02.023, 02.099, 02.104, 02.131, 02.136, 02.155, 02.187, 07.161, 07.210, 09.281 and 09.282]
in FGE.205Rev1. These substances can now be evaluated via the Procedure.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
The use of ﬂavourings is regulated under Regulation (EC) No 1334/20081 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
On 27 September 2012, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids adopted an opinion on Flavouring Group Evaluation 205 (FGE.205): consideration of
genotoxic potential on a,b-unsaturated aliphatic ketones with terminal double bonds and precursors
from chemical subgroup 1.2.2 of FGE.19.
The Panel concluded that for the two representative substances oct-1-en-3-one [FL-no: 07.081] and
pent-1-en-3-one [FL-no: 07.102], the positive effects in the bacterial mutagenicity assays cannot be
overruled by one negative and one equivocal gene mutation test in mammalian cells. Accordingly, an
in vivo Comet assay on the ﬁrst site of contact (e.g. the stomach or duodenum) and on the liver is
requested for the most potent substance, pent-1-en-3-one. As an alternative, a transgenic animal
assay would also be acceptable.
On 10 March 2015, the applicant submitted additional studies on the representative substances
[FL-no: 07.102] and [FL-no: 07.081]. These studies are intended to cover the substances in this group,
namely: FL-nos: 02.023, 02.099, 02.104, 02.131, 02.136, 02.155, 02.187, 07.161, 07.210, 09.281 and
09.282.
1.1.1. Terms of Reference
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this
new information and, depending on the outcome, proceed to the full evaluation on the above
mentioned ﬂavouring substances in accordance with Commission Regulation (EC) No 1565/2000.
2. Data and methodologies
2.1. History of the evaluation of FGE.19 substances
Flavouring Group Evaluation 19 (FGE.19) contains 360 ﬂavouring substances from the EU Register
being a,b-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl
substances via hydrolysis and/or oxidation (EFSA, 2008a).
The a,b-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA,
2008a). The Panel noted that there were limited genotoxicity data on these ﬂavouring substances but
that positive genotoxicity studies were identiﬁed for some substances in the group.
The a,b-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a
(quantitative) structure–activity relationship (Q)SAR prediction of the genotoxicity of these substances
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE Models and
ISS-Local Models (Gry et al., 2007)).
The Panel noted that for most of these models internal and external validation has been performed,
but considered that the outcome of these validations was not always extensive enough to appreciate
the validity of the predictions of these models for these a,b-unsaturated carbonyls. Therefore, the
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list
of ﬂavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council,
introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing
Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
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Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided
not to take substances through the procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions using two ISS Local Models (Benigni and Netzeva,
2007a,b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the fact that
there are available data on genotoxicity, in vitro and in vivo, as well as data on carcinogenicity for
several substances. Based on these data, the Panel decided that 15 subgroups (1.1.1, 1.2.1, 1.2.2,
1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 2008b) could not be evaluated
through the Procedure due to concern with respect to genotoxicity. Corresponding to these subgroups,
15 FGEs were established: FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224
and 225.
For 11 subgroups, the Panel decided, based on the available genotoxicity data and (Q)SAR
predictions, that a further scrutiny of the data should take place before requesting additional data
from the Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203,
210, 212, 213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218, it was
concluded that a genotoxic potential could be ruled out and accordingly these substances were
evaluated using the Procedure. For all or some of the substances in the remaining FGEs, FGE.201,
203, 210, 212, 213, 216, 217 and 220, the genotoxic potential could not be ruled out.
To ease the data retrieval of the large number of structurally related a,b-unsaturated substances
in the different subgroups for which additional data are requested, EFSA worked out a list of
representative substances for each subgroup (EFSA, 2008c). Likewise, a EFSA genotoxicity expert group
has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b).
The Flavouring Industry has been requested to submit additional genotoxicity data according to the
list of representative substances and test strategy for each subgroup.
The Flavouring industry has now submitted additional data and the present FGE concerns the
evaluation of these data requested on genotoxicity.
2.2. Presentation of the substances in ﬂavouring group evaluation 205
Flavouring Group Evaluation 205 (FGE.205), corresponding to subgroup 1.2.2 of FGE.19, concerns
four a,b-unsaturated aliphatic ketones with a terminal double bond and nine precursors for such
ketones. The 13 substances under consideration in the present evaluation are listed in Table 3.
Nine of the 13 substances have previously been evaluated by the Joint FAO/WHO Expert
Committee on Food Additives (JECFA) at their 59th and 69th meetings (JECFA, 2002, 2009). A
summary of their current evaluation status by JECFA and the outcome of this consideration is
presented in Table 4.
The a,b-unsaturated aldehyde and ketone structures are considered to be structural alerts for
genotoxicity (EFSA, 2008a) and the data on genotoxicity previously available did not rule out the
concern for genotoxicity.
The Panel has identiﬁed two substances in subgroup 1.2.2 which will represent the other
11 substances in this subgroup (EFSA, 2008c). For these two substances, genotoxicity data according
to the test strategy (EFSA, 2008b) have been requested. The representative substances are listed in
Table 1.
Table 1: Representative substances for subgroup 1.2.2 of FGE.19
FL-no
JECFA-no
EU Register name Structural formula
FEMA no
CoE no
CAS no
07.081
1148
Oct-1-en-3-one O 3515
2312
4312-99-6
07.102
1147
Pent-1-en-3-one O 3382
11179
1629-58-9
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives;
FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstracts Service.
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2.3. History of the evaluation of the substances belonging to FGE.205
Subgroup 1.2.2 was one of the FGE.19 subgroups for which the Panel concluded that, based on the
available data, additional genotoxicity data were necessary to perform the risk assessment for these
substances (EFSA, 2008a).
In 2012, the Industry submitted genotoxicity data for the two representative substances. Oct-1-en-
3-one [FL-no: 07.081] was tested in an Ames test, a hypoxanthine-guanine phosphoribosyl transferase
(hprt) assay and an in vitro micronucleus assay. Pent-1-en-3-one [FL-no: 07.102] was tested in an
in vitro micronucleus assay and a hprt assay. These studies were evaluated in FGE.205 (EFSA CEF
Panel, 2012) where the Panel concluded that the positive effects in the bacterial mutagenicity assays
of the two representative substances cannot be overruled by the one negative and one equivocal gene
mutation test in mammalian cells. The Panel recommended to test in vivo the most potent of the
representative substances, pent-1-en-3-one, in a Comet assay on the ﬁrst site of contact (e.g. the
stomach or duodenum) and on the liver.
FGE Adopted by EFSA Link
No. of
substances
FGE.205 27 September 2012 http://www.efsa.europa.eu/en/efsajournal/pub/2902 13
FGE.205Rev1 23 June 2016 http://www.efsa.europa.eu/en/efsajournal/pub/4535 13
FGE: Flavouring Group Evaluation; EFSA: European Food Safety Authority.
The applicant has submitted two in vivo studies: a combined micronucleus assay and comet assay
for pent-1-en-3-one [FL-no: 07.102] and a comet assay for oct-1-en-3-one [FL-no: 07.081].
The present Revision 1 of FGE.205 (FGE.205Rev1) concerns the evaluation of a combined bone
marrow micronucleus test and Comet assay with scoring in the liver and duodenum of rats for pent-1-
en-3-one, and an Ames test and a Comet assay with scoring in the liver of rats for oct-1-en-3-one.
Section 2.4 is identical to the text presented in FGE.205. Text presented in Section 3 is the
evaluation of the new data in FGE.205Rev1.
2.4. Additionally genotoxicity data considered by the Panel in FGE.2054
The Industry has submitted data concerning genotoxicity studies (EFFA, 2011) for the two
representative substances of this subgroup:
• Oct-1-en-3-one (amyl vinyl ketone) [FL-no: 07.081]
• Pent-1-en-3-one (ethyl vinyl ketone) [FL-no: 07.102]
2.4.1. In vitro data
An Ames test, a hprt assay and an in vitro micronucleus assay have been performed with oct-1-en-
3-one [FL-no: 07.081]. An in vitro micronucleus assay and a hprt assay have been performed with
pent-1-en-3-one [FL-no: 07.102]. Besides these new studies submitted by Industry, some older studies
already considered by the Panel (EFSA, 2008a) with pent-1-en-3-one were included in the submission.
An overview of the studies are summarised in Table 5.
2.4.1.1. Oct-1-en-3-one (amyl vinyl ketone) [FL-no: 07.081]
Bacterial reverse mutation assay
An Ames assay was conducted with oct-1-en-3-one in Salmonella typhimurium strains TA98, TA100,
TA1535, TA1537 and TA102 to assess the mutagenicity of oct-1-en-3-one, both in the absence and in
the presence of metabolic activation by S9-mix, in three experiments. An initial toxicity range-ﬁnding
experiment was carried out in the absence and in the presence of S9-mix in strain TA100 only, using
ﬁnal concentrations of oct-1-en-3-one at 1.6, 8, 40, 200, 1,000 and 5,000 lg/plate, plus negative
(solvent) and positive controls. Evidence of toxicity was apparent on all plates treated at 200 lg/plate
and above in the absence and in the presence of S9-mix. Based on this toxicity data, the following
concentrations were used for all tester strains in the ﬁrst experiment: 0.32, 1.6, 8, 40, 200 and
1,000 lg/plate. Following these treatments, evidence of toxicity was observed in all strains at
concentrations of 200 and/or 1,000 lg/plate, both in the absence and in the presence of S9-mix.
4 Data presented in Section 2.4 are cited from the ﬁrst opinion on FGE.205.
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Negative results were obtained for all strains with and without S9-mix, except for TA100 with S9-mix
where a statistically signiﬁcant increase in the number of revertants above the control was observed at
40 lg/plate where the number of revertants increased 1.2-fold and at 200 lg/plate with an increase of
4.6-fold. Toxicity was observed at 1,000 lg/plate (Beevers, 2009).
In the second experiment, plate incorporation treatments of all the tester strains were performed in
the absence of S9-mix, with the maximum test concentration reduced to 500 lg/plate to account for a
revised estimate of the toxicity limit. In addition, all treatments in the presence of S9-mix were further
modiﬁed by the inclusion of a preincubation step to increase the range of mutagenic detection. Following
these treatments, evidence of toxicity was observed in all strains at concentrations of 125 or 250 lg/plate
and above in the absence of S9-mix, and at 62.5 lg/plate and above in the presence of S9-mix. No
statistically signiﬁcant increases in the number of revertants were seen in any strain except TA100.
Without S9-mix, the number of revertants in strain TA100 increased 1.2- and 1.4-fold at 62.5 and
125 lg/plate, respectively, and with S9-mix treatment a 1.2-fold increase was observed at 31.25 lg/plate.
These increases are below the threshold that is normally considered biologically relevant, which is a
twofold increase threshold. In addition to the preincubation treatments described above (with S9-mix),
plate incorporation treatments of strain TA100 in the presence of S9-mix were performed at 50, 100, 200,
300, 400 and 500 lg/plate. Evidence of toxicity was observed on all plates treated at 300 lg/plate and
above, but there were no statistically signiﬁcant increases in revertant numbers at any concentration.
In the third experiment, only the TA100 strain was evaluated as it was weakly positive in the
previous experiments. Plate incorporation treatments in the absence and presence of S9-mix were
performed at 100, 125, 150, 175, 200, 225, 250 and 300 lg/plate. Preincubation treatments solely in
the presence of S9-mix were performed at 15, 30, 45, 60, 75, 90 105 and 120 lg/plate. Following
these treatments, evidence of toxicity was observed at 225 or 250 lg/plate and above (plate
incorporation treatments in the absence or presence of S9-mix, respectively) and at 60 lg/plate
(preincubation treatments). The plate incorporation method resulted in increased revertants by 2.3- to
3-fold at treatment concentrations of 125–200 lg/plate in the absence of S9-mix, and 2.2- to 2.9-fold
at treatment concentrations of 100–200 lg/plate in the presence of S9-mix. In both cases, the
increases were not concentration related. Using preincubation methodology, a 1.7-fold increase in
revertants was observed at 45 lg/plate treatments in the presence of S9-mix.
Overall, small but statistically signiﬁcant (Dunnett’s test, 1% level) increases in revertant numbers
were observed following oct-1-en-3-one treatments of strain TA100 both in the absence and in the
presence of metabolic activation by S9-mix. This weak mutagenic response was not reproduced on
every experimental occasion, but where signiﬁcant increases were observed they were small in
magnitude and limited by toxicity at the next highest oct-1-en-3-one concentrations. The lack of
consistent reproducibility of this weak mutagenic response was attributed to variation in toxicity among
experiments, and to a small window where mutagenic responses could be observed.
The Panel concluded that oct-1-en-3-one is a weak inducer of mutations in the TA100 strain of
S. typhimurium when tested up to toxic concentrations in the absence and in the presence of a rat
liver metabolic activation system.
hprt assay
In the light of the weak positive result in the Ames test, it was deemed relevant by the applicant to
assess oct-1-en-3-one for its ability to induce mutation at the hprt locus in mouse lymphoma cells. The
study consisted of two cytotoxicity range-ﬁnding experiments followed by three separate experiments.
Two experiments were conducted for 3 h in the absence and in the presence of metabolic activation
by an Aroclor 1254-induced rat liver post-mitochondrial fraction (S9-mix), followed by a third
experiment conducted for 24 h in the absence of S9-mix. In the cytotoxicity range-ﬁnding experiment
using a 3-h treatment, 10 concentrations were tested in the absence and in the presence of S9-mix,
ranging from 2.5 to 1,262 lg/mL (10 mM). The highest concentrations not resulting in severe
cytotoxicity were 2.5 lg/mL in the absence of S9-mix and 4.9 lg/mL in the presence of S9-mix, which
gave 2% and 9% relative survival (RS), respectively. In the cytotoxicity range-ﬁnding experiment using
24-h treatment, nine concentrations were tested in the absence of S9-mix, ranging from 0.01 to
3 lg/mL. The highest concentration to provide > 10% RS was 1.5 lg/mL, which gave 22% RS. Based
on this range-ﬁnding study, 12 concentrations from 0.05 to 2.5 lg/mL in the absence of S9-mix and
from 0.5 to 7.5 lg/mL in the presence of S9-mix were tested in the ﬁrst mutation experiment using
3-h treatment and 7 days recovery period. The highest non-toxic concentrations were 2 lg/mL in
the absence of S9-mix and 3 lg/mL in the presence of S9-mix, which gave 12% and 19%
RS, respectively. In the absence of S9-mix, a statistically signiﬁcant increase in mutant frequency
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(MF; 4.23 mutants per 106 viable cells compared to the mean vehicle control MF of 1.10 mutants per
106 viable cells) was observed at the highest concentration (2 lg/mL), but there was no statistically
signiﬁcant linear trend (Lloyd, 2011c).
In the second experiment using 3-h treatment, 10 concentrations ranging from 0.5 to 3 lg/mL in
the absence of S9-mix, and from 0.5 to 4.5 lg/mL in the presence of S9-mix, were tested. As the
highest concentration evaluated in the ﬁrst experiment (2 lg/mL) resulted in a RS < 10%, the highest
concentration evaluated in the second experiment was 1.8 lg/mL in the absence of S9-mix (11% RS)
and 4.5 lg/mL in the presence of S9-mix (24% RS). There were no statistically signiﬁcant increases in
MF at any concentration analysed or linear trends. The small increase in MF observed in the ﬁrst
experiment was therefore not reproduced (Lloyd, 2011c).
In the third experiment using 24-h treatment in the absence of S9-mix, 11 concentrations ranging
from 0.1 to 2.5 lg/mL were tested. Seven days after treatment, the highest concentration not too
toxic for selection (1.2 lg/mL) resulted in 16% RS. Mutant frequencies in all treated cultures were
lower than in the concurrent control (Lloyd, 2011c).
In this study, high cytotoxicity was observed, which complicates the evaluation of oct-1-en-3-one
for genotoxicity in mammalian cells. Some indication of genotoxicity was observed in the absence of
S9-mix at the highest non-toxic concentration tested (2 lg/mL) and 3-h treatment, which however
could not be reproduced in the second experiment using the same treatment conditions and a third
experiment using 24-h treatment. It is therefore concluded that this gene mutation test is negative
under the experimental conditions performed.
In vitro micronucleus assays
Oct-1-en-3-one was tested in an in vitro micronucleus assay using duplicate human lymphocyte
cultures prepared from the pooled blood of two female donors both in the absence and in the
presence of metabolic activation (S9-mix).
After stimulation for 48 h with phytohaemagglutinin (PHA), cells were treated with oct-1-en-3-one for
3 h (followed by 21 h recovery) with and without S9-mix and for 24 h without S9-mix. An initial range-
ﬁnding experiment using 4.6–1,262 lg/mL oct-1-en-3-one (i.e. up to 10 mM) was performed. Based on
the cytotoxicity data obtained in this study, measured by effect on the replication index (RI),
concentrations ranging from 2 to 20 lg/mL (absence of S9-mix) or 5 to 40 lg/mL (presence of S9-mix)
were chosen for the main experiment with 3-h treatment. The 3 + 21 h treatment in the absence of S9-
mix resulted in 81–99% toxicity at 10 lg/mL and above. Concentrations of 2, 4, and 8 lg/mL resulted in
0.20–0.35% micronucleated binucleated (MNBN) cell frequency which was below that of the concurrent
control. The 3 + 21 h treatment in the presence of S9-mix resulted in 81% cytotoxicity or greater at
concentrations of 20 lg/mL and above. Treatments at 5, 10 and 15 lg/mL resulted in MNBN cell
frequencies (0.3–0.55%) similar to that of the control (0.5%) (Lloyd, 2011b).
Since the 3-h treatment produced negative results for micronucleus (MN) induction, treatments
were also performed over a 24-h period in the absence of S9. In the range-ﬁnding experiment,
concentrations again ranged up to 1,262 lg/mL (10 mM) but cells did not replicate (zero RI) at
concentrations of 35.33 lg/mL and above. Also, there was 94% toxicity at 12 lg/mL. Therefore,
10 lg/mL was chosen as the top concentration, where RI was reduced by 62%. Treatment at this
concentration resulted in a statistically signiﬁcant (p < 0.01) increase in mean MNBN cell frequency to
1.65% (concurrent control was 0.65%). However, the MNBN frequency only exceeded the normal
range in one of the two replicate cultures, and there was no increase in MNBN frequency at 8 lg/mL
where reduction in RI was 58%, or any of the lower concentrations. Given that the only positive
response was in one replicate at toxicity exceeding 60% and that at the recommended range toxicity
(58%), there was no increase in MN frequency, this is considered to be an indirect consequence of
high levels of toxicity and is not considered a biologically relevant positive response.
Taken as a whole, treatment with oct-1-en-3-one at acceptable levels of toxicity resulted in
frequencies of MNBN cells that were generally similar to (and not signiﬁcantly different from) those
observed in concurrent vehicle controls. It was concluded that oct-1-en-3-one did not induce
micronuclei in cultured human peripheral blood lymphocytes when tested up to toxic concentrations for
3 + 21 h in the absence and in the presence of S9-mix and for 24 + 0 h in the absence of S9-mix
(Lloyd, 2011b).
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2.4.1.2. Pent-1-en-3-one (ethyl vinyl ketone) [FL-no: 07.102] – previously available
in vitro data
Bacterial reverse mutation assay
In a study by Deininger et al. (1990), pent-1-en-3-one was tested for the induction of gene
mutations in S. typhimurium strain TA100 both with and without Aroclor-induced rat liver S9-mix. The
preincubation method was used. The substance, dissolved in DMSO, was tested up to 2 lmol/plate. In
the absence of S9-mix, toxicity was observed at a concentration of 0.6 lmol/plate while no toxicity
was observed with S9-mix up to the highest tested concentration. Ethyl vinyl ketone was clearly
genotoxic both with and without S9-mix. The speciﬁc mutagenicity, calculated as the linear slope of
the dose–response curve, was 1,293 revertants per lmol without S9-mix and 748 revertants per lmol
with S9-mix. Although the peak revertant rate was higher with S9-mix (1,250 revertants at about
2 lmol/plate) than without S9-mix (675 revertants at 0.5 lmol/plate), the speciﬁc mutagenicity was
higher in the absence of S9-mix. This indicates that the effect of S9-mix is detoxiﬁcation. However, in
supplementary studies with the enzyme inhibitor SKF 525 (an inhibitor of monooxygenase), the
mutagenic response disappeared completely, whereas an addition of trichloropropene oxide (TCPO, an
inhibitor of epoxide hydrolase) resulted in an increase in mutagenic activity, indicating that epoxidation
of the double bond by S9-mix could also play a role in the mutagenicity of pent-1-en-3-one. This
data was also included in a paper from the same research group together with data for other
a,b-unsaturated ketones and aldehydes (Eder et al., 1993). The same study group also isolated and
characterised guanine and deoxyguanosine adducts with pent-1-en-3-one, indicating that pent-1-en-3-
one can form DNA adducts, which can give rise to mutations (Eder et al., 1991, 1993). The mutagenic
effect in S. typhimurium TA100 was supported by genotoxicity in the SOS chromotest performed with
the Escherichia coli strain PQ37 both with and without S9-mix. Genotoxicity was only observed in the
presence of S9-mix. The maximum induction factor was 1.83 which is above the limit of 1.5 for a
positive response (Deininger et al., 1990; Eder et al., 1991, 1993). Pent-1-en-3-one was more
genotoxic in the SOS chromotest than methyl vinyl ketone (Eder et al., 1993).
Based on these studies, it was concluded that pent-1-en-3-one is genotoxic in bacteria.
2.4.1.3. Pent-1-en-3-one (ethyl vinyl ketone) [FL-no: 07.102] – new available in vitro
data
Because of the previously reported positive Ames test with pent-1-en-3-one (Deininger et al.,
1990), a mammalian cell gene mutation test was performed in mouse lymphoma L5178Y cells and
evaluated for induction of forward mutations at the hprt locus.
hprt assay
Induction of forward mutations at the hprt locus after treatment with pent-1-en-3-one in the
absence and in the presence of S9-mix was evaluated. Concentrations for the main experiment were
established by a preliminary range-ﬁnding cytotoxicity experiment. In the ﬁrst mutation experiment,
cell cultures treated with pent-1-en-3-one for 3 h at 0.6, 0.7, 0.8, 0.85, 0.95 and 1.0 lg/mL in the
absence of S9-mix and at 1.5, 2, 2.5, 3, 3.25, 3.5, 3.75, 4, 4.5 and 5 lg/mL in the presence of S9-mix
were evaluated. Per cent relative survival (%RS) decreased to 16% and 19% at the highest
concentrations of 0.95 and 1.0 lg/mL treatment without S9-mix, respectively. No signiﬁcant increases
in MF were observed at any concentration in the absence of S9-mix. In the presence of S9-mix, the
highest concentration, 5 lg/mL, resulted in 21% RS. One statistically signiﬁcant (Dunnett’s test, 5%
level) increase in MF from the control (2.48 mutants per 106 viable cells) was observed at the second
highest concentration, 4.5 lg/mL, (8.7 mutants per 106 viable cells) in the presence of S9-mix in both
cultures. A statistically signiﬁcant linear trend was also observed, although the MF value at the highest
concentration tested (5 lg/mL) was not signiﬁcantly different from the solvent control (5.42 mutants
per 106 viable cells) (Lloyd, 2011a).
Thus, additional experiments were undertaken evaluating MF after 3-h treatment with pent-1-en-3-one
in the presence of S9-mix but also after 24-h treatment in the absence of S9-mix (two separate
experiments). In the presence of S9-mix, the highest concentration evaluated (7 lg/mL) reduced RS
to 8%, and therefore exceeded the required level of toxicity. There were no statistically signiﬁcant
increases in MF at any concentration analysed and no statistically signiﬁcant linear trend. Cultures
treated at 4.5 lg/mL gave a 41% RS compared to a 36% RS in ﬁrst experiment and did not result in
increased mutation frequency. The signiﬁcant increase in mutation frequency observed at a single
concentration in the ﬁrst experiment was not reproduced in the second experiment under the same
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treatment conditions even at higher and more toxic concentrations (the maximum concentrations
analysed were 5 and 7 lg/mL in the ﬁrst and second experiments, respectively). Following 24-h
treatment in the absence of S9-mix, the top concentrations evaluated (1.0 and 0.8 lg/mL in the two
separate experiments) reduced RS to 12% in each case, and therefore achieved the required level of
toxicity for a robust test. There were no statistically signiﬁcant increases in MF at any concentration
and no signiﬁcant linear trend in either of the two 24-h experiments. The Panel noted that in this
in vitro assay pent-1-en-3-one is also cytotoxic to mouse lymphoma L5178Y cells, which could mask a
genotoxic effect. Also, in this hprt assay, there was some indication of genotoxicity at the second
highest concentration and a linear trend in the presence of S9-mix after 3-h treatment. Although this
positive effect was not reproduced in a second experiment using the same experimental design and a
third experiment using 24-h treatment without S9-mix, it was concluded by the Panel that the results
in this in vitro gene mutation test is equivocal (Lloyd, 2011a).
In vitro micronucleus assays
Pent-1-en-3-one was assayed for the induction of structural and numerical chromosomal
aberrations in mammalian cells in vitro by examining the effect on the frequency of micronuclei in
cultured human peripheral blood lymphocytes pooled from two healthy male donors both in the
absence and in the presence of Aroclor-induced rat liver S9-mix. After stimulation with PHA for 48 h,
cells were treated with pent-1-en-3-one either for 3 h (followed by 21 h of recovery) in the absence or
in the presence of S9-mix, or for 24 h in the absence of S9-mix. A range-ﬁnding experiment had been
conducted with and without S9-mix at 12 concentrations up to 841.2 lg/mL (10 mM). In the main
assay, micronuclei were analysed at three concentrations for each treatment group. For 3-h treatment
without S9-mix, the concentrations were 3.5, 4.25 and 4.75 lg/mL, for 3-h treatment with S9-mix the
concentrations were 8.0, 12.0 and 16.0 lg/mL, and for 24-h treatment without S9-mix the
concentrations were 3.0, 3.5 and 4.0 lg/mL. The levels of cytotoxicity (reduction in RI) analysed for
micronucleus at the top concentrations reached 48% and 50% in the 3-h treatment in the presence of
S9-mix and the 24-h treatment in the absence of S9-mix, respectively. Following a 3-h treatment in the
absence of S9-mix, toxicity at the highest concentration (4.75 lg/mL) was only 38%. However, the
toxicity curve was very steep and at the next higher concentration (5.0 lg/mL) toxicity was excessive
(81% reduction in RI). One thousand binucleate cells per culture from two (or in some cases four)
replicate cultures per concentration were scored for micronuclei.
Following the 3-h treatment without S9-mix, there was an increase in the frequency of MNBN cells
from 0.2% in the solvent control to 0.55% at the lowest concentration. This increase was statistically
signiﬁcant at p < 0.05 but fell well within the historical control range and was therefore not considered
to be biologically signiﬁcant. There were no signiﬁcant increases in MNBN frequency at the middle and
high concentrations, and therefore no concentration-related response. In the presence of S9-mix,
there were no statistically signiﬁcant increases in mean MNBN cell frequency at any concentration.
Following the 24-h treatment without S9-mix, a statistically signiﬁcant (p < 0.01) increase in MNBN
cell frequency from 0.40% in the control to 1.1% was observed at the maximum concentration of
4.0 lg/mL. This elevated frequency, which only just exceeded the historical control range for the
laboratory (0–1.0%), was due entirely to an increase in MNBN frequency in only one of the two
replicate cultures (the other replicate had a background MNBN frequency at a comparable level of
toxicity), and the overall responses were not clearly concentration related. Thus, it seems most likely
that the single replicate increase was due to chance. Treatment of the cells with pent-1-en-3-one
under all conditions therefore resulted in frequencies of MNBN cells that were generally similar to those
observed in concurrent and historical vehicle controls at all concentrations analysed (Lloyd, 2010). It
was concluded by the applicant that pent-1-en-3-one did not induce micronuclei in cultured human
peripheral blood lymphocytes when tested at toxic concentrations in both the absence and the
presence of S9-mix (Lloyd, 2010).
The Panel noted that pent-1-en-3-one is extremely cytotoxic to human lymphocytes, with a very
steep toxicity curve and therefore the substance can only be tested for genotoxicity in a narrow
concentration range.
A summary of the in vitro genotoxicity date are given in Table 5.
2.4.2. In vivo data
No data available.
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2.4.3. Conclusion by the CEF Panel in FGE.205
The two representative substances, oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one [FL-no:
07.102], were both weakly genotoxic in bacteria with pent-1-en-3-one being the most potent
(previously available data). In newly available data performed according to recent guidelines and Good
Laboratory Practice (GLP), several studies were performed on oct-1-en-3-one in bacteria. In these
assays, the test substance was highly cytotoxic with a steep toxicity curve, and there was a lack of
reproducibility in the weak genotoxic response, which could be due to a slight day-to-day variation in
the severity of the observed toxicity and a very narrow concentration range resulting in mutagenicity.
Both substances were also tested in mammalian cells for gene mutations at the hprt locus and for
structural and numerical chromosomal aberrations in the micronucleus assay. Also in mammalian cells,
the test substances were highly cytotoxic. All the in vitro assays were well performed and each of the
assays performed in mammalian cells were considered to be negative, when looking at them
separately except the gene mutation assay with pent-1-en-3-one which was considered by the Panel to
be equivocal, presumably due to severe cytotoxicity of the test compound. Due to positive effects in
the bacterial mutagenicity assays of the two representative substances, which cannot be overruled by
one negative and one equivocal gene mutation test in mammalian cells, an in vivo Comet assay on the
ﬁrst site of contact (e.g. the stomach or duodenum) and on the liver is requested on the most potent
substance, pent-1-en-3-one. As an alternative, a transgenic animal assay would also be acceptable.
3. Assessment
3.1. Additionally genotoxicity data considered by the Panel in
FGE.205Rev1
In response to the data request in FGE.205, the Industry has submitted in vivo data on both pent-
1-en-3-one [FL-no: 07.102] and oct-1-en-3-one [FL-no: 07.081] (Table 2).
Furthermore, to investigate the mechanism of action of the mutagenic activity seen in the bacterial
reverse mutation tests by Beevers (2009 – described in Section 2.4.1), a new Ames test with oct-1-en-
3-one was performed (Bowen, 2013). The study was performed according to OECD Guideline 471
(OECD, 1997), but not fully compliant with this guideline as only a single strain of bacteria was tested.
The strain TA100 was chosen because mutagenicity was observed only in this strain (Beevers, 2009).
3.1.1. Pent-1-en-3-one (ethyl vinyl ketone) [FL-no: 07.102]
Pent-1-en-3-one was tested for its potential to induce micronuclei in the polychromatic erythrocytes
(PCE) of the bone marrow of treated rats and to induce DNA damage in the liver (Keig-Shevlin, 2015b)
and duodenum (Keig-Shevlin, 2015c) of the same animals (Table 6).
Pent-1-en-3-one dissolved in corn oil was administered by gavage to male Han Wistar rats (six
animals per dose group and 3 animals in the positive control group) at doses of 0, 10, 20 and 40 mg/kg
body weight (bw) per day in three administrations at 0 (day 1), 24 (day 2) and 45 (day 3) h. The dose
levels were identiﬁed in a dose-range ﬁnding study, in which morbidity and mortality have been
observed at 60 mg/kg bw and higher doses and which demonstrated no gender differences.
Accordingly, the authors of this study considered 40 mg/kg bw per day as the maximum tolerated dose
(MTD). Ethyl methanesulfonate (EMS) was used as positive control, 150 mg/kg bw per day, dosed at
0, 24 and 45 h.
At day 3 (48 h) bone marrow (MN assessment), liver and duodenum (Comet analysis and
histopathology) were sampled at necropsy, as well as blood for clinical chemistry.
Clinical chemistry showed that at 40 mg/kg bw per day there were decreases in alkaline
phosphatase (ALP) activity (229  70.4 IU/L in the negative control, 110  16 IU/L at the highest
Table 2: In vivo studies for the representative substances of FGE.205Rev1
Substance FL-no In vivo study Reference
Pent-1-en-3-one 07.102 Combined micronucleus (in bone marrow) and
comet assay (in the liver and duodenum)
Keig-Shevlin (2015b,c)
Oct-1-en-3-one 07.081 Comet assay in the liver Keig-Shevlin (2015a)
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number.
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dose tested), total protein (55  1.5 g/L in the negative control, 47  2.6 g/L at the highest dose
tested), albumin (36  1 g/L in the negative control, 26  1.5 g/L at the highest dose tested),
albumin/globulin ratio (2  0.12 in the negative control, 1.3  0.23 at the highest dose tested),
sodium (138  1.6 mmol/L in the negative control, 133  2.4 mmol/L at the highest dose tested) and
calcium (2.64  0.093 mmol/L in the negative control, 2.46 + 0.071 mmol/L at the highest dose
tested). There were no changes in either microscopic or macroscopic examinations which were related
to the administration of pent-1-en-3-one. The Panel noted that the changes in clinical chemistry
parameters cannot be considered as an indication of the liver toxicity, however, they might be due to
general toxicity and could, in this case, be considered as an indirect indication of systemic availability.
Accordingly, the negative outcome of this study can be considered valid.
3.1.1.1. Micronucleus arm of the assay
Animals treated with pent-1-en-3-one at all doses exhibited group mean %PCE that were either
similar or demonstrated a slight reduction when compared to the concurrent vehicle control group and
which were within the laboratory’s historical vehicle control data, thus conﬁrming there was no
evidence of test article related bone marrow toxicity.
Animals displayed intragroup heterogeneity in the low-dose group (10 mg/kg bw per day).
Therefore, the percentages of micronucleated polychromatic erythrocytes (MN PCE) in each treated
group were compared with vehicle control using a Wilcoxon rank sum test. In addition, the Terpstra–
Jonckheere test for dose response was performed.
Animals treated with pent-1-en-3-one at all doses exhibited MN PCE frequencies that were similar
to the concurrent vehicle control group and which were considered consistent with the laboratory’s
historical vehicle control data. There were no statistically signiﬁcant increases in micronucleus
frequency for any of the groups receiving the test article, compared with the concurrent vehicle control
(Keig-Shevlin, 2015b).
3.1.1.2. Comet arm of the assay
Liver
Following oral gavage administration of pent-1-en-3-one [FL-no: 07.102], there was no dose-related
increase in the percentage of clouds in the liver, demonstrating that treatment with pent-1-en-3-one
did not cause excessive liver toxicity which can interfere with Comet analysis.
Group mean percentage of tail intensity and tail moment values for all tested doses were similar to
the concurrent vehicle control group. There was no evidence of any induction of DNA damage in cells
isolated from the liver following treatment with pent-1-en-3-one (Keig-Shevlin, 2015b).
Duodenum
There was no dose-related increase in the percentage of clouds in duodenum cells following
treatment with pent-1-en-3-one, thus demonstrating that treatment did not cause toxicity that could
have interfered with Comet analysis.
Group mean percentage of tail intensity and tail moment values for all groups treated with pent-1-
en-3-one were comparable with the group mean vehicle control data. There were no statistically
signiﬁcant differences in %tail intensity between treated and the vehicle control group. All individual
animal data for tail intensity and tail moment, at all dose levels, were generally consistent with the
vehicle control data and fell within the laboratory’s historical control data, with the exception of
2 animals at the highest dose which fell below the historical control range observed for tail intensity.
For one of these two animals, also the value of tail moment fell below the historical control range
(Keig-Shevlin, 2015c).
3.1.1.3. Conclusion for pent-1-en-3-one
It is concluded that under the conditions of this study, pent-1-en-3-one [FL-no: 07.102], did not
induce DNA damage in the liver and duodenum when male rats were dosed orally up to 40 mg/kg bw
per day (an estimate of the MTD). Pent-1-en-3-one [FL-no: 07.102] did not increase the percentage of
micronucleated PCE in bone marrow. The question whether or not the bone marrow was exposed is
not relevant in this case because a previous in vitro micronucleus assay was negative and, accordingly,
there was no need of follow-up with an in vivo micronucleus assay.
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3.1.2. Oct-1-en-3-one (amyl vinyl ketone) [FL-no: 07.081]
Oct-1-en-3-one was tested in an Ames test (Bowen, 2013) in order to investigate the mechanism of
action inducing mutagenicity in the bacterial reverse mutation tests by Beevers (2009 – described in
Section 2.4.1). Oct-1-en-3-one was tested also through an in vivo Comet assay in rats in the liver
(Keig-Shevlin, 2015a) for its potential to induce DNA damage (Tables 6 and 7).
3.1.2.1. Bacterial reverse mutation assay
Oct-1-en-3-one [FL-no: 07.081] has previously been tested for mutagenic effect in S. typhimurium
TA100 (Beevers, 2009, see Section 2.4.1). A weak positive effect was observed, without consistent
reproducibility, due to high toxicity of the test substance. A follow-up study has been submitted by
industry (Bowen, 2013). In this study, oct-1-en-3-one (purity 98.4%) was tested in the Ames test
(plate incorporation) at concentrations of 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 lg/plate, only in
strain TA100 of S. typhimurium, in two separate experiments, in the presence and in the absence of
metabolic activation, using triplicate plates. Negative and positive controls were included in
quintuplicate and triplicate, respectively. In both experiments, oct-1-en-3-one was tested in the
presence and in the absence of each of four distinct free radical/electrophile scavengers, in order to
assess the role of the potential formation of reactive oxygen species in the mechanism inducing
mutagenicity in strain TA100. The free radical/electrophile scavengers used were: glutathione at
500 lg/plate, N-acetyl cysteine at 500 lg/plate, catalase at 12.5 lg/plate and 2,5-dimethylfuran at
250 lg/plate (Table 7).
This study conﬁrmed the high bacterial toxicity of oct-1-en-3-one. It induced cytotoxicity from
concentrations of 125 and 250 lg/plate in the ﬁrst and second experiment, respectively, without
S9-mix, and from concentrations of 250 and 500 lg/plate with S9-mix. When the electrophile scavengers
were added, there was a slight reduction in bacterial toxicity, but there was a difference in toxicity
between the two experiments. In the absence of free radical/electrophile scavengers, oct-1-en-3-one
increased the number of revertants, compared with the concurrent vehicle control, at least twofold or
1.5-fold, in the absence or in the presence of S9-mix, respectively, at 62.5 and 125 lg/plate.
There was no clear indication of the inﬂuence on the mutagenic effect of oct-1-en-3-one when the
electrophile scavengers were added.
Overall, the applicant concluded that oct-1-en-3-one induced mutations in S. typhimurium TA100
under the conditions of the study, and that glutathione, N-acetyl cysteine and to a lesser extent 2,5-
dimethylfuran reduced the mutagenic response. In contrary, catalase increased the mutagenic
response in most cases. According to the applicant, these results indicate that the mutagenic effect is
due to oxidative stress.
The Panel, however, noted that the results were not clearly reproducible and that the mutagenic
responses were weak in all experiments. Therefore, the Panel concluded that no clear conclusion on
the mechanism of mutagenicity induced by oct-1-en-3-one and by the other substances in this group
can be drawn based on this study. The Panel noted that probably, the reduction in the number of
revertants, observed in particular after the treatment with glutathione and N-acetyl cysteine, is due to
a reduction in bacterial toxicity. In addition, strain TA102 is more sensitive to oxidative stress than
TA100, but oct-1-en-3-one was negative in strain TA102 in a previous mutagenicity test. The
Panel considered that the newly submitted study (Bowen, 2013) does not contribute in elucidating the
mechanism of genotoxicity of oct-1-en-3-one [FL-no: 07.081].
3.1.2.2. Comet assay
Oct-1-en-3-one [FL-no: 07.081] dissolved in corn oil was administered by gavage to male Han
Wistar rats (six animals per dose group and three animals in the positive control group) at doses of
0, 45, 90 and 180 mg/kg bw per day in two administrations at 0 (day 1) and 21 (day 2) h. The dose
levels were identiﬁed in a dose-range ﬁnding study, which also demonstrated no gender differences.
EMS was used as positive control, 200 mg/kg bw, in a single administration at 21 h (day 2).
At day 2 (24 h), liver and duodenum were sampled at necropsy, as well as blood and tissue for
clinical chemistry and histopathology. The duodenum, however, was not analysed in the comet assay.
There were no ﬁndings either in clinical chemistry, microscopic or macroscopic examinations which
were related to the administration of oct-1-en-3-one.
There was no dose-related increase in clouds percentage in the liver following treatment with oct-1-
en-3-one, thus demonstrating that treatment with oct-1-en-3-one did not cause excessive toxicity,
which can interfere with Comet analysis, following oral gavage administration.
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Following treatment with oct-1-en-3-one at all dose levels, group mean %tail intensity and tail
moment values for all tissues were similar to the concurrent vehicle control group. There was no
evidence of any induction of DNA damage in cells isolated from the liver following treatment with
oct-1-en-3-one.
The Panel noted that all group mean values for %tail intensity and tail moment were very low
including the positive control that was below the historical control range. Therefore, the
Panel considered this study to be of limited validity.
3.1.2.3. Conclusion for oct-1-en-3-one
Oct-1-en-3-one [FL-no: 07.081] induced gene mutations in S. typhimurium strain TA100 in the
presence and in the absence of S9-mix. It was negative in the hprt assay and in the in vitro
micronucleus assay (EFSA CEF Panel, 2012). New available data conﬁrm the high toxicity of oct-1-en-
3-one and its mutagenicity on strain TA100.
The bacterial reverse mutation assay on TA100 in the presence of free radical/electrophile
scavengers does not allow to elucidate the mechanism of gene mutations induced by oct-1-en-3-one.
The in vivo comet assay in the liver did not provide evidence of any induction of DNA damage in the
liver, however, this study is considered of limited validity.
4. Overall conclusion
Due to positive effects in the bacterial mutagenicity assays of the two representative substances
pent-1-en-3-one [FL-no: 07.102] and oct-1-en-3-one [FL-no: 07.081], an in vivo Comet assay on the
ﬁrst site of contact (e.g. the stomach or duodenum) and on the liver was requested on the most
potent substance, pent-1-en-3-one (EFSA CEF Panel, 2012).
In response to the data request in FGE.205, the industry has submitted in vivo data on both pent-
1-en-3-one and oct-1-en-3-one. Pent-1-en-3-one [FL-no: 07.102] was tested for its potential to induce
micronuclei in the PCE of the bone marrow of treated rats and to induce DNA damage in the liver and
duodenum of the same animals. Oct-1-en-3-one [FL-no: 07.081], was tested, in a Comet assay, for its
potential to induce DNA damage in the liver of rats. Furthermore, to investigate the mechanism of
action of the mutagenic activity observed in the bacterial reverse mutation tests of previous studies, a
new Ames test with oct-1-en-3-one was performed with strain TA100.
Pent-1-en-3-one [FL-no: 07.102] tested in vivo in a combined micronucleus and comet assay did
not show genotoxic effects in either the liver or duodenum of treated rats. The negative results of the
bone marrow micronucleus assay are considered inconclusive because there is no evidence of bone
marrow exposure to the tested substance. However, as results of the in vitro micronucleus assay were
negative, no additional in vivo follow-up studies on clastogenicity and aneugenicity were needed.
The bacterial mutation assay provided for oct-1-en-3-one [FL-no: 07.081] conﬁrms the weak
mutagenic effect in bacteria shown in previous studies, but does not clarify the mechanism of action.
The liver comet assay is considered of limited validity due to low values of mean tail intensity and tail
moment. However, based on the data available on the most potent of the two representative
substances for subgroup 1.2.2, pent-1-en-3-one [FL-no: 07.102], the Panel concluded that there is no
concern for genotoxicity and accordingly all the 13 substances in subgroup 1.2.2 [FL-no: 02.023,
02.099, 02.104, 02.131, 02.136, 02.155, 02.187, 07.081, 07.102, 07.161, 07.210, 09.281 and 09.282]
can be evaluated using the Procedure.
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Summary of speciﬁcations
Table 3: Summary of speciﬁcations for the substances in the Flavouring Group Evaluation 205 (JECFA,
2002, 2009)
FL-no
JECFA-no
EU Register
name
Structural
formula
FEMA no
CoE no
CAS no
Phys.
form
Mol.
formula
Mol.
weight
Solubility(a)
Solubility in
ethanol(b)
Boiling
point, °C(c)
Melting
point, °C
ID test
Assay
minimum
Refrac.
index(d)
Spec.
gravity(e)
02.023
1152
Oct-1-en-3-ol OH 2805
72
3391-86-4
Liquid
C8H16O
128.22
Insoluble
Miscible
175–175.2
NMR
96%
1.431–1.442
0.835–0.845
02.099
1150
Pent-1-en-3-ol
OH
3584
11717
616-25-1
Liquid
C5H10O
86.13
Sparsely
soluble
Miscible
114
NMR
98%
1.419–1.427
0.831–0.837
02.104
1151
Hex-1-en-3-ol OH 3608
10220
4798-44-1
Liquid
C6H12O
100.16
Insoluble
Miscible
133.5–134
NMR
98%
1.425–1.431
0.830–0.836
02.131 But-3-en-2-ol OH
598-32-3
Liquid
C4H8O
72.11
Slightly
soluble
Freely soluble
90
MS
95%
1.409–1.415
0.831–0.837
02.136
1153
Dec-1-en-3-ol OH 3824
51100-54-0
Liquid
C10H20O
156.27
Slightly
soluble
Miscible
215
NMR MS
97%
1.439–1.446
0.836–0.842
02.155
1842
1-Hepten-3-ol
OH
4129
10218
4938-52-7
Liquid
C7H14O
114.19
Practically
insoluble or
insoluble
Freely soluble
155
MS
97%
1.431–1.437
0.834–0.837
02.187 Non-1-en-3-ol OH
10291
21964-44-3
Liquid
C9H18O
142.24
Practically
insoluble or
insoluble
Freely soluble
195
MS
98%
1.438–1.444
0.835–0.845
07.081
1148
Oct-1-en-3-one O 3515
2312
4312-99-6
Liquid
C8H14O
126.20
Insoluble
Miscible
37–38
(3 hPa)
NMR
96%
1.428–1.439
0.813–0.819
07.102
1147
Pent-1-en-3-one O 3382
11179
1629-58-9
Liquid
C5H8O
84.12
Insoluble
Miscible
68–70
(260 hPa)
NMR
97%
1.417–1.422
0.842–0.848
07.161 Hex-1-en-3-one O
1629-60-3
Liquid
C6H10O
98.14
Practically
insoluble or
insoluble
Freely soluble
128
MS
95%
1.420–1.426
0.849–0.855
07.210 1-Nonene-3-one O
24415-26-7
Liquid
C9H16O
140.22
Insoluble
Freely soluble
80 (16 hPa)
MS
95%
1.436–1.442
0.826–0.830
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Summary of safety evaluation of the JECFA substances in FGE.205
FL-no
JECFA-no
EU Register
name
Structural
formula
FEMA no
CoE no
CAS no
Phys.
form
Mol.
formula
Mol.
weight
Solubility(a)
Solubility in
ethanol(b)
Boiling
point, °C(c)
Melting
point, °C
ID test
Assay
minimum
Refrac.
index(d)
Spec.
gravity(e)
09.281
1836
Oct-1-en-3-yl
acetate
O
O
3582
11716
2442-10-6
Liquid
C10H18O2
170.25
Practically
insoluble or
insoluble
Freely soluble
80 (2 hPa)
NMR
97%
1.418–1.428
0.865–0.886
09.282
1837
Oct-1-en-3-yl
butyrate
O
O
3612
16491-54-6
Liquid
C12H22O2
198.32
Practically
insoluble or
insoluble
Freely soluble
81
(0.46 hPa)
IR NMR MS
95%
1.418–1.428
0.865–0.875
FL-no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; EU: European Union; FEMA: Flavor and
Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstracts Service; ID: identity; NMR: nuclear magnetic
resonance; MS: mass spectrometry; IR: infrared.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1,013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
Table 4: Current safety evaluation status applying the Procedure, based on the MSDI approach, (JECFA,
2002, 2009)
FL-no
JECFA-no
EU Register
name
Structural
formula
EU MSDI(a)
US MSDI
(lg/capita
per day)
Class(b)
Evaluation
procedure(c)
JECFA outcome
on the named
compound(d or e)
EFSA conclusion
for genotoxicity
02.023
1152
Oct-1-en-3-ol OH 240
23
Class III
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
02.099
1150
Pent-1-en-3-ol
OH
2.1
1
Class II
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
02.104
1151
Hex-1-en-3-ol OH 0.55
2
Class II
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
02.131 But-3-en-2-ol OH 0.0012 Class II
No evaluation
Not evaluated by
JECFA
Genotoxicity
concern could be
ruled out
02.136
1153
Dec-1-en-3-ol OH ND
0.1
Class II
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
02.155
1842
1-Hepten-3-ol
OH
0.13 Class II
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
02.187 Non-1-en-3-ol OH 0.58 Class II
No evaluation
Not evaluated by
JECFA
Genotoxicity
concern could be
ruled out
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Genotoxicity data considered by the Panel in FGE.205
FL-no
JECFA-no
EU Register
name
Structural
formula
EU MSDI(a)
US MSDI
(lg/capita
per day)
Class(b)
Evaluation
procedure(c)
JECFA outcome
on the named
compound(d or e)
EFSA conclusion
for genotoxicity
07.081
1148
Oct-1-en-3-one O 1.2
0.1
Class II
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
07.102
1147
Pent-1-en-3-one
O
0.29
0.1
Class II
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
07.161 Hex-1-en-3-one O 0.012 Class II
No evaluation
Not evaluated by
JECFA
Genotoxicity
concern could be
ruled out
07.210 1-Nonene-3-one O 0.0012 Class II
No evaluation
Not evaluated by
JECFA
Genotoxicity
concern could be
ruled out
09.281
1836
Oct-1-en-3-yl
acetate
O
O
2.1 Class I
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
09.282
1837
Oct-1-en-3-yl
butyrate
O
O
0.0012 Class I
A3: intake
below
threshold
(d) Genotoxicity
concern could be
ruled out
JECFA: The Joint FAO/WHO Expert Committee on Food Additives; FGE: Flavouring Group Evaluation; FL-no: FLAVIS number;
EU: European Union; MSDI: maximised survey-derived daily intake; EFSA: European Food Safety Authority; ND: Not determined.
(a): EU MSDI: Amount added to food as ﬂavour in (kg/year) 9 10E9/(0.1 9 population in Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita
per day.
(b): Thresholds of concern: Class I = 1,800 lg/person per day, Class II = 540 lg/person per day, Class III = 90 lg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
Table 5: Summary of genotoxicity data considered by the Panel in FGE.205
FL-no
Chemical
name
Test system
in vitro
Test object
Concentrations
tested and test
conditions
Result Reference Comments
[07.102] Pent-1-en-
3-one
Reverse
mutation
Salmonella
typhimurium
TA100
0–168.33
lg/plate(a,b,e)
Positive Deininger
et al.
(1990)
Highly toxic especially without
S9. Mutagenicity observed with
and without S9. Reduced
mutagenicity with inhibition of
monooxygenase, enhanced
mutagenicity with addition of
epoxide hydrolase
Not reported Positive Eder et al.
(1993)
Assay conditions, doses and
control revertants were not
reported but same data as in
Deininger et al. (1990)
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FL-no
Chemical
name
Test system
in vitro
Test object
Concentrations
tested and test
conditions
Result Reference Comments
SOS
chromotest
Escherichia coli
PQ37
0–5.05 lg(a) Positive Deininger
et al.
(1990)
Highly toxic. Positive in the
presence of S9-mix (induction
factor of 1.83)
0–8.41 lg(a) Positive Eder et al.
(1991)
Reported in graphical form for
methyl vinyl ketone only, but
patterns were noted to be
similar for pent-1-en-3-one,
previously published by
Deininger et al. (1990)
0–8.41 lg(a) Positive Eder et al.
(1993)
DNA adducts E. coli PQ37 168 mg Positive Eder et al.
(1993)
1,N2-cyclic deoxyguanosine
adducts and 7-linear guanine
adducts were isolated
hprt assay Mouse lymphoma
L5178Y cells
0.1–1.2 lg/mL(d,j)
0.5–5 lg/mL(f,j)
0.1–1.2 lg/mL(d,k)
2–7 lg/mL(f,j)
0.25–1.1 lg/mL(d,k)
Equivocal Lloyd
(2011a)
Highly toxic. Could only be
tested in a narrow
concentration range. Some
indication of genotoxic effect at
toxic concentrations, which was
not reproducible
Micronucleus
induction
Human peripheral
blood lymphocytes
3.50–4.75
lg/mL(d,g)
8–16 lg/mL(f,g)
3–4 lg/mL(d,h)
Negative Lloyd
(2010)
Highly toxic. Could only be
tested in a narrow
concentration range. Some
indication of genotoxic effect at
toxic concentrations, which was
not reproducible
[07.081] Oct-1-en-
3-one
Reverse
Mutation
S. typhimurium
TA98, TA100,
TA1535, TA1537
and TA102
0.32–1,000
lg/plate(b)
Positive Beevers
(2009)
All strains were negative except
TA100, with S9-mix treatment
at 200 lg/plate resulted in
4.6-fold increase in revertants.
Toxicity was observed at
1,000 lg/plate
S. typhimurium
TA98, TA100,
TA1535, TA1537
and TA102
15.6–500
lg/plate(b,c,i)
Negative All strains were negative,
except that TA100 showed a
slight 1.4-fold increase in
revertants at the highest
nontoxic concentration of
125 lg/plate without S9-mix
treatment, and a 1.2-fold
increase with S9-mix at
31.25 lg/plate Both effects
were signiﬁcant but not
biologically relevant (twofold
over control levels). All results
from preincubation cohort were
negative
S. typhimurium
TA100
50–500
lg/plate(c,f)
Negative
S. typhimurium
TA100
100–300
lg/plate(b,c)
15–120 lg/plate(f,i)
Positive The plate incorporation method
resulted in increased revertants
by 2.3- to 3-fold with a 125–
200 lg/plate treatment in the
absence of S9-mix and 2.2- to
2.9-fold with a 100–200 lg/plate
treatment in the presence of
S9-mix, neither being dose
dependent. The only
preincubation treatment that
resulted in increased revertants
was 45 lg/plate treatments in
the presence of S9-mix (1.7-fold)
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FL-no
Chemical
name
Test system
in vitro
Test object
Concentrations
tested and test
conditions
Result Reference Comments
hprt assay Mouse lymphoma
L5178Y cells
0.05–2.5 lg/mL(d,j)
0.5–7.5 lg/mL(f,j)
0.5–3 lg/mL(d,j)
0.5–4.5 lg/mL(f,j)
0.1–2.5 lg/mL(d,k)
Negative Lloyd
(2011c)
Highly toxic. Could only be
tested in a narrow
concentration range. Some
indication of genotoxic effect at
toxic concentrations, which was
not reproducible
Micronucleus
induction
Human peripheral
blood lymphocytes
2–20 lg/mL(d,g)
5–40 lg/mL(f,g)
2–20 lg/mL(d,k)
Negative Lloyd
(2011b)
Highly toxic. Could only be
tested in a narrow
concentration range. Some
indication of genotoxic effect at
toxic concentrations, which was
not reproducible
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number.
(a): Values were converted from reported lM or nM concentrations to lg values.
(b): With and without S9 metabolic activation.
(c): Plate incorporation method.
(d): Without S9 metabolic activation.
(e): Preincubation method.
(f): With S9 metabolic activation.
(g): 3-h incubation with 21-h recovery period.
(h): 24-h incubation with no recovery period.
(i): Preincubation method with S9 metabolic activation.
(j): 3 h treatment.
(k): 24 h treatment.
Table 6: Summary of genotoxicity data considered by the panel in FGE.205Rev1
Chemical
name
FL-no
Test system
in vivo
Test object Route Dose Result Reference Comments
Pent-1-en-3-one
[07.102]
Micronucleus
assay
Han Wistar
Rat; M
Gavage 0, 10, 20 and
40 mg/kg bw
per day
Negative Keig-Shevlin
(2015b,c)
Study performed in
accordance with OECD
guideline 474 and GLP. No
proof of bone marrow
exposure
Comet assay Han Wistar
Rat; M
Gavage Negative(a,b) Study performed in
accordance with OECD
guideline 489 and GLP
Oct-1-en-3-one
[07.081]
Comet assay Han Wistar
Rat; M
Gavage 0, 45, 90 and
180 mg/kg bw
per day
Inconclusive(a) Keig-Shevlin
(2015a)
Study performed in
accordance with GLP and
internationally recognised
protocols available before the
publication of OECD guideline
489. The study was considered
of limited validity
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number; bw: body weight; OECD: Organisation for Economic Co-operation and Development;
GLP: Good Laboratory Practice.
(a): Scored in liver cells.
(b): Scored in duodenum cells.
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Documentation provided to EFSA
1) Beevers, 2009. Reverse mutation in ﬁve histidine-requiring strains of Salmonella
typhimurium. Oct-1-en-3-one. Covance Laboratories Ltd, England. Study no. 8200445.
November 2009. Unpublished report submitted by EFFA to FLAVIS Secretariat.
2) Benigni R and Netzeva T, 2007a. Report on a QSAR model for prediction of genotoxicity of
a,b-unsaturated aldehydes in S. typhimurium TA100 and its application for predictions on
a,b-unsaturated aldehydes in Flavouring Group Evaluation 19 (FGE.19). Unpublished report
submitted by FLAVIS Secretariat to EFSA.
3) Benigni R and Netzeva T, 2007b. Report on a QSAR model for prediction of genotoxicity of
a,b-unsaturated ketones in S. typhimurium TA100 and its application for predictions on
a,b-unsaturated aldehydes in Flavouring Group Evaluation 19 (FGE.19). Unpublished report
submitted by FLAVIS Secretariat to EFSA.
4) Bowen R, 2013a. Oct-1-en-3-one: Investigation into the mechanism of mutagenicity: reverse
mutation in one histidine-requiring strain of Salmonella typhimurium. Covance Laboratories
Ltd. Study no. 8281446. 7 August 2013. Unpublished report submitted to by EFFA.
5) EFFA (European Flavour Association), 2011. Submission by the European Flavour
Association to the European Food Safety Authority. Flavouring Group Evaluation 19
Subgroup 1.2.2 (corresponding to FGE.205): Submission of additional data related to
FGE.19 subgroup 1.2.2. 16 December 2011. FLAVIS/8.138.
6) Gry J, Beltoft V, Benigni R, Binderup M-L, Carere A, Engel K-H, G€urtler R, Jensen GE,
Hulzebos E, Larsen JC, Mennes W, Netzeva T, Niemel€a J, Nikolov N, Nørby KK and Wedebye
EB, 2007. Description and validation of QSAR genotoxicity models for use in evaluation of
ﬂavouring substances in Flavouring Group Evaluation 19 (FGE.19) on 360 a,b-unsaturated
aldehydes and ketones and precursors for these. Unpublished report submitted by FLAVIS
Secretariat to EFSA.
7) Keig-Shevlin Z, 2015a. 1-Octen-3-one: Rat alkaline Comet assay. Covance Laboratories Ltd.
Study no. 8302486. 04 March 2015. Unpublished ﬁnal report submitted by EFFA.
8) Keig-Shevlin Z, 2015b. Pent-1-en-3-one: Rat micronucleus and alkaline Comet assay.
Covance Laboratories Ltd. Study no. 8302945. 12 February 2015. Unpublished ﬁnal report
submitted by EFFA.
9) Keig-Shevlin Z, 2015c. Pent-1-en-3-one: Analysis of duodenum Comet slides from Covance
study 8302945. Covance Laboratories Ltd. Study no. 8326425. 07 October 2015.
Unpublished ﬁnal report submitted by EFFA.
10) Lloyd M, 2010. Induction of micronuclei in cultured human peripheral blood lymphocytes.
Pent-1-en-3-one. Covance Laboratories Ltd. Study no. 8200539. April 2010. Unpublished
report submitted by EFFA to FLAVIS Secretariat.
11) Lloyd M, 2011a. Mutation at the hprt locus of mouse lymphoma L5178Y cells using the
Microtitre(R) ﬂuctuation technique. Pent-1-en-3-one. Covance Laboratories LTD. Study no.
8243352. August 2011. Unpublished report submitted by EFFA to FLAVIS Secretariat.
12) Lloyd M, 2011b. Induction of micronuclei in cultured human peripheral blood lymphocytes.
Oct-1-en-3-one. Covance Laboratories LTD. Study no. 8226885. January 2011. Unpublished
report submitted by EFFA to FLAVIS Secretariat.
Table 7: In vitro study to investigate the mechanism of mutagenicity induced by oct-1-en-3-one in
S. typhimurium strain TA100
Chemical
name
[FL-no]
Test system
in vitro
Test object
Concentrations
tested and test
conditions
Result Reference Comments
Oct-1-en-3-one
[07.081]
Bacterial reverse
mutation assay
Salmonella
typhimurium
TA100
7.8–500
lg/plate(a,b)
Positive Bowen
(2013)
Highly toxic
especially without
S9. Mutagenicity
observed with and
without S9
FL-no: FLAVIS number.
(a): With and without metabolic activation.
(b): The following free radical/electrophile scavengers were added: glutathione, N-acetyl cysteine, catalase, 2,5-dimethylfuran.
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13) Lloyd M, 2011c. Mutation at the hprt locus of mouse lymphoma L5178Y cells (MLA) using
the Microtitre(R) ﬂuctuation technique. Oct-1-en-3-one. Covance Laboratories LTD. Study
no. 8233101. May 2011. Unpublished report submitted by EFFA to FLAVIS Secretariat.
14) Nikolov N, Jensen GE, Wedebye EB and Niemel€a J, 2007. Report on QSAR predictions of
222 a,b-unsaturated aldehydes and ketones from Flavouring Group Evaluation 19 (FGE.19)
on 360 a,b-unsaturated aldehydes and ketones and precursors for these. Unpublished
report submitted by FLAVIS Secretariat to EFSA.
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Abbreviations
ALP alkaline phosphatase
bw body weight
CAS Chemical Abstracts Service
CEF Scientiﬁc Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CoE Council of Europe
EFFA European Flavour Association
EMS ethyl methanesulfonate
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS Flavour Information System database
GLP Good Laboratory Practice
HPRT hypoxanthine-guanine phosphoribosyl transferase
ID identity
IR infrared
JECFA The Joint FAO/WHO Expert Committee on Food Additives
MF mutant frequency
MN micronucleus
MNBN micronucleated binucleated (cells)
MN PCE micronucleated polychromatic erythrocytes
MS mass spectrometry
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MSDI maximised survey-derived daily intake
MTD maximum tolerated dose
NMR nuclear magnetic resonance
OECD Organisation for Economic Co-operation and Development
PCE polychromatic erythrocytes
PHA phytohaemagglutinin
(Q)SAR (quantitative) structure–activity relationship
RI replication index
RS relative survival
TCPO trichloropropene oxide
WHO World Health Organization
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